A vs. NBIX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at A and NBIX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | A | NBIX |
|---|---|---|
| Company Name | Agilent Technologies, Inc. | Neurocrine Biosciences, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 40.15 billion USD | 13.59 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | November 18, 1999 | May 23, 1996 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of A and NBIX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | A | NBIX |
|---|---|---|
| 5-Day Price Return | 14.46% | -2.31% |
| 13-Week Price Return | 16.69% | 6.13% |
| 26-Week Price Return | 21.08% | 23.90% |
| 52-Week Price Return | -3.34% | 20.25% |
| Month-to-Date Return | 10.35% | -2.39% |
| Year-to-Date Return | 5.43% | 0.39% |
| 10-Day Avg. Volume | 1.89M | 0.97M |
| 3-Month Avg. Volume | 1.84M | 0.90M |
| 3-Month Volatility | 33.89% | 27.64% |
| Beta | 1.27 | 0.28 |
Profitability
Return on Equity (TTM)
A
19.97%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
A’s Return on Equity of 19.97% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
NBIX
13.22%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, NBIX’s Return on Equity of 13.22% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
A
17.97%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
A’s Net Profit Margin of 17.97% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
NBIX
13.88%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
NBIX’s Net Profit Margin of 13.88% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
A
21.26%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
A’s Operating Profit Margin of 21.26% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
NBIX
19.72%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
NBIX’s Operating Profit Margin of 19.72% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | A | NBIX |
|---|---|---|
| Return on Equity (TTM) | 19.97% | 13.22% |
| Return on Assets (TTM) | 10.14% | 9.39% |
| Net Profit Margin (TTM) | 17.97% | 13.88% |
| Operating Profit Margin (TTM) | 21.26% | 19.72% |
| Gross Profit Margin (TTM) | 52.92% | 98.49% |
Financial Strength
Current Ratio (MRQ)
A
2.25
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
A’s Current Ratio of 2.25 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
NBIX
3.20
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
NBIX’s Current Ratio of 3.20 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
A
0.54
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
A’s Debt-to-Equity Ratio of 0.54 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
NBIX
0.00
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
NBIX’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
A
254.50
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
With an Interest Coverage Ratio of 254.50, A demonstrates a superior capacity to service its debt, placing it well above the typical range for the Life Sciences Tools & Services industry. This stems from either robust earnings or a conservative debt load.
NBIX
6.75
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
NBIX’s Interest Coverage Ratio of 6.75 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | A | NBIX |
|---|---|---|
| Current Ratio (MRQ) | 2.25 | 3.20 |
| Quick Ratio (MRQ) | 1.71 | 3.10 |
| Debt-to-Equity Ratio (MRQ) | 0.54 | 0.00 |
| Interest Coverage Ratio (TTM) | 254.50 | 6.75 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
A
0.71%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.71%, A offers a more attractive income stream than most of its peers in the Life Sciences Tools & Services industry, signaling a strong commitment to shareholder returns.
NBIX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
A
22.95%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
A’s Dividend Payout Ratio of 22.95% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
NBIX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | A | NBIX |
|---|---|---|
| Dividend Yield (TTM) | 0.71% | 0.00% |
| Dividend Payout Ratio (TTM) | 22.95% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
A
32.40
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
A’s P/E Ratio of 32.40 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
NBIX
38.87
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
NBIX’s P/E Ratio of 38.87 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
A
5.82
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
A’s P/S Ratio of 5.82 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
NBIX
5.39
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
NBIX’s P/S Ratio of 5.39 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
A
5.12
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
A’s P/B Ratio of 5.12 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
NBIX
4.62
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
NBIX’s P/B Ratio of 4.62 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | A | NBIX |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 32.40 | 38.87 |
| Price-to-Sales Ratio (TTM) | 5.82 | 5.39 |
| Price-to-Book Ratio (MRQ) | 5.12 | 4.62 |
| Price-to-Free Cash Flow Ratio (TTM) | 36.33 | 25.61 |